1.7298
1.15%
-0.0202
Schlusskurs vom Vortag:
$1.75
Offen:
$1.71
24-Stunden-Volumen:
102.48K
Relative Volume:
0.09
Marktkapitalisierung:
$5.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.07M
KGV:
-0.269
EPS:
-6.4313
Netto-Cashflow:
$-12.56M
1W Leistung:
-8.96%
1M Leistung:
-29.11%
6M Leistung:
-62.56%
1J Leistung:
-80.72%
Palisade Bio Inc Stock (PALI) Company Profile
Firmenname
Palisade Bio Inc
Sektor
Branche
Telefon
(858) 704-4900
Adresse
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Vergleichen Sie PALI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.7471 | 5.15M | 0 | -14.07M | -12.56M | -13.99 |
VRTX
Vertex Pharmaceuticals Inc
|
407.92 | 105.01B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.17B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
629.39 | 37.48B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 30.94B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
114.13 | 27.15B | 3.30B | -501.07M | 1.03B | -2.1146 |
Palisade Bio Inc Aktie (PALI) Neueste Nachrichten
Palisade Bio (NASDAQ:PALI) Trading Up 2.9% – Here’s What Happened - Defense World
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - Markets Insider
Dr. Brian Feagan Appointed to Palisade Bio Clinical Advisory Board - citybiz
Palisade Bio Strengthens Clinical Advisory Board with Leading Gastroenterology Expert for UC Drug Development - StockTitan
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewswire
Palisade Bio Raises $5M in Public Offering to Advance Phase 1 Clinical Trial Pipeline - StockTitan
What's Going On With Palisade Bio Stock On Thursday? - Benzinga
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - The Manila Times
Palisade Bio Raises $5M in Public Offering to Advance Key Clinical Trial of PALI-2108 - StockTitan
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
PALI Stock Plummets to 52-Week Low at $2.13 Amid Market Struggles - Investing.com
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire
Palisade Bio Reports Promising Safety Data in Phase 1 Ulcerative Colitis Drug Trial | PALI Stock News - StockTitan
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
Brookline Capital Management Estimates Palisade Bio FY2024 Earnings - Defense World
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
Palisade Bio's PALI-2108 Shows Promise in Preclinical IBD Treatment Study | PALI Stock News - StockTitan
Brookline Capital Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - MSN
ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Palisade Bio Inc (PALI) Quarterly 10-Q Report - Quartzy
Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire
Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan
Palisade Bio initiates phase 1 study of new UC drug - Investing.com
Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times
Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire
Palisade Bio Launches Phase 1 Trial for Novel Ulcerative Colitis Drug PALI-2108 | PALI Stock News - StockTitan
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com
Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK
HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times
Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World
Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia
Palisade Bio receives Health Canada nod for UC drug trial - Investing.com
Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World
Finanzdaten der Palisade Bio Inc-Aktie (PALI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Palisade Bio Inc-Aktie (PALI) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Wei Binxian | Director |
Nov 21 '24 |
Option Exercise |
0.00 |
388 |
0 |
855 |
Wei Binxian | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
465 |
0 |
467 |
Williams Donald Allen | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
340 |
0 |
340 |
Jones Mitchell Lawrence | Chief Medical Officer |
May 28 '24 |
Option Exercise |
0.00 |
4,290 |
0 |
4,313 |
Finley John David | CEO, CFO, Director |
May 28 '24 |
Option Exercise |
0.00 |
7,068 |
0 |
14,079 |
Williams Donald Allen | Director |
May 28 '24 |
Buy |
4.86 |
1,000 |
4,863 |
1,000 |
Finley John David | CEO, CFO, Director |
May 24 '24 |
Buy |
4.81 |
1,000 |
4,810 |
8,437 |
Jones Mitchell Lawrence | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
460 |
0 |
880 |
Finley John David | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
443 |
0 |
6,832 |
Finley John David | CEO, CFO, Director |
Mar 11 '24 |
Option Exercise |
0.00 |
5,558 |
0 |
96,849 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):